Search Results

Eli Lilly’s investment in the LEAP Research and Innovation District in Lebanon, Indiana, has now jumped to more than $13 billion.

Amid shortages of its Mounjaro and Zepbound blockbuster drugs, Eli Lilly on Friday said it is investing an additional $5.3 billion in its production site in Lebanon, Indiana, to boost output of their active ingredient.

Eli Lilly and Company announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company’s total investment in this site from $3.7 billion to $9 billion.

Versiti, a national leader in blood health innovation, announced the acquisition of Quantigen, a specialty lab based in Fishers, Indiana.

Scilex Holding Company announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List effective October 1, 2023.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

OrthoPediatrics Corp. a company focused exclusively on advancing the field of pediatric orthopedics, announced it was recently named one of the 2023 Best Places to Work in Indiana.

Panbela Therapeutics, Inc. (Nasdaq: PBLA) today announced that it has commenced a Phase II double-blind, randomized study to evaluate CPP-1X-T (Eflornithine tablets) for recent onset type 1 diabetes, in collaboration with Indiana University School of Medicine and funded by JDRF, the leading global type 1 diabetes research and advocacy organization.